Activity/Study
Status
Results expected
Production of recombinant molecule and variant(s)
Quantities to cover validation phase
Completed
January 2019
Bioequivalence study in animal model and dose response
Experiments completed report ongoing
Q4 2019
Pharmacokinetic study
Completed September 2019
In-depth study on mechanism of action, UZH
Ongoing
Q2 2020
Lead validation
Positive preliminary results
Q4 2019
Activity/Study
Production of recombinant molecule and variant(s)
Status: Completed
Quantities cover validation and preclinical studies
Status: January 2019
Bioequivalence study in animal models and dose response
Status: April 2019
Results expected: June 2019
Pharmacokinetics study
Status: selection of CRO
Results expected: Q2 2019
Postdoc study on mechanism of action, UZH
Status: April 2019
Results expected: Q3 2019
GBCHpVac has secured exclusive, worldwide commercialization rights to GBC-R1 from the University of Zurich.
In a first phase, GBC SA has financed the patenting of GBC-R1. See also WO2015/114575 and WO2015/144576.